Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS
Document Type and Number:
WIPO Patent Application WO/2016/108045
Kind Code:
A4
Abstract:
The invention discloses compounds of the formula wherein A, B, X, Y and Z are defined. The compounds of the invention show activity against a range of bacteria, and are useful in the treatment or prophylaxis of a bacterial infection in an animal.

Inventors:
POTTER BARRY VICTOR LLOYD (GB)
DOHLE WOLFGANG (GB)
SU XIANGDONG (GB)
NORMANTON JOHN (GB)
DUDLEY EDWARD (GB)
NIGAM YAMNI (GB)
Application Number:
PCT/GB2015/054170
Publication Date:
October 27, 2016
Filing Date:
December 29, 2015
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV SWANSEA (GB)
UNIV BATH (GB)
International Classes:
C07C279/04; A61K31/155; C07C279/18; C07C281/18
Attorney, Agent or Firm:
BRADLEY, Adrian (10 Fetter Lane, London Middlesex EC4A 1BR, GB)
Download PDF:
Claims:
AMENDED CLAIMS

received by the International Bureau on 14 September 2016 (14.09.2016)

Claims

1. A compound of Formula I

I

wherein

A is an optionally substituted aryl or heteroaryl group;

B is an optionally substituted aryl or heteroaryl group; and

X is a group -CH20-;

Y is selected from methylene, C=0, C(R5)=N, and -CH20-;

Z is a group

R is selected from H and (Cl-C6)alkyl;

R6, R7, and R8 are independently selected from H, (Cl-C6)alkyl, CN, N02, (Cl-C6)acyl, NH2, NH(C1-C6)alkyl, N((Cl-C6)alkyl)2, and (Cl-C6)alkoxyalkyl;

R9 is selected from O, S, SO, S02, NR10, and CRnR12;

R10 is selected from H, (Cl-C6)alkyl, CN, N02, (Cl-C6)acyl, NH2, NH(C1-C6)alkyl, N((C1- C6)alkyl)2, C(=NH)NH2, and (C1-C6) alkoxyalkyl;

Rn and R12 are independently selected from H, (Cl-C6)alkyl, CN, and N02;

or, taken together with the atoms to which they are attached, R 6u and R 7', R 7' and R 8°, R 8° and R 10 , R6 and R10, R6 and Rn, or R8 and Rn form an optionally substituted 3 to 6 membered heteroaryl or heterocyclyl ring optionally containing 1 or 2 further heteroatoms selected from O, N and S;

or, taken together with the atoms to which they are attached, R6, R7, R8, R10, or Rn form an optionally substituted 3 to 6 membered heteroaryl or heterocyclyl ring fused to ring A, or a pharmaceutically active salt or N-oxide thereof.

2. A compound according to claim 1 , wherein A is an aryl group selected from phenyl, thiazolyl, pyridyl, imidazolyl, and benzothiazole.

46

3. A compound according to claim 1 or 2 wherein A is a phenyl group, optionally substituted with from one to three groups independently selected from halo, C1-C6 alkyl, Cl- C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, nitro, cyano and C1-C6 thioalkyl.

4. A compound according to claim 3, wherein the compound has the formula

wherein Q is optionally present and represents from one to three groups independently selected from halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, nitro, cyano and C1-C6 thioalkyl.

5. A compound according any preceding claim, wherein B is an aryl group selected from phenyl, thiazolyl, pyridyl, and benzothiazole.

6. A compound according to claim 5, wherein B is a phenyl group, optionally substituted with from one to three groups independently selected from halo, C1-C6 alkyl, Cl- C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, nitro, cyano and C1-C6 thioalkyl.

7. A compound according to claim 1, wherein Y is CH=N.

8. A compound according to any preceding claim, wherein R9 is NR10, with R10 as defined in claim 1.

9. A compound according to claim 8, wherein R10 is H.

10. A compound according to any preceding claim, wherein R6, R7 and R8 are all H.

11. A compound according to claim 1 which is one of

l-[({3-[(2,3-dichlorophenyl)methoxy]phenyl}methylidene)amino]guanidine; l-{ [(3-{ [2- chloro-3-(trifluoromethyl)phenyl]methoxy}phenyl)methylidene]amino} guanidine; 7-[(2,3- dichlorophenyl)methoxy]-l,2,3,4 etrahydroisoquinoline-2-carboximidamide; 5-[(2,3- dichlorophenyl)methoxy] - 1 ,2,3 ,4-tetrahydroisoquinoline-2-carboximidamide ; l-({3-[(2,3- dichlorophenyl)methoxy] phenyl } methyl) - 1 -methylguanidine ; l-({3-[(2,3 -dichlorophenyl) methoxy]phenyl}methyl)-l-(2-methoxyethyl) guanidine; 3-({3-[(2,3-dichlorophenyl)methoxy] phenyl}methyl)-l-methylguanidine; (E)-Amino(2-(2-chloro-3-((2-chloro-3-methoxybenzyl) oxy)benzylidene) hydrazinyl)methanimine; (E)-Amino(2-(3-(benzyloxy)-2-chlorobenzylidene) hydrazinyl)methanimine; (E)-Amino(2-(2-chloro-3-((4-chlorobenzyl)oxy)benzylidene) hydrazinyl)methanimine; (E)-Amino(2-(2-chloro-3-((2,3-dichlorobenzyl)oxy)benzylidene) hydrazinyl)methanimine; (E)-Amino(2-(2-chloro-3-((2-chloro-3-(trifluoromethyl)benzyl)oxy) benzylidene) hydrazinyl)methanimine; (E)-Amino(2-(2-chloro-3-((2,4-dichlorobenzyl) oxy)benzylidene)hydrazinyl) methanimine(E)-Amino(2-(2-chloro-3-((2,5-dichlorobenzyl)oxy) benzylidene)hydrazinyl) methanimine; (E)-Amino(2-(2-chloro-3-((3,4-dichlorobenzyl)oxy)

47 benzylidene)hydrazinyl) methanimine; (E)-Amino(2-(2-chloro-3-((2,3,5-trichlorobenzyl)oxy) benzylidene)hydrazinyl) methanimine; (E)-Amino(2-(2-chloro-3-((3-(trifluoromethyl)benzyl) oxy)benzylidene)hydrazinyl) methanimine ; (E)- Amino(2-(2-chloro-3 -((4-(trifluoromethyl) benzyl)oxy)benzylidene)hydrazinyl) methanimine; l-[(3-{ [2-chloro-3-

(trifluoromethyl)phenyl]methoxy}phenyl)methyl]guanidine; l-({3-[(2,3- dichlorophenyl)methoxy]phenyl}methyl)guanidine; l-(4-((2,3-dichlorobenzyl)oxy)benzyl) guanidine; l-({3-[(2,3-dichlorophenyl)methoxy]-2,6-difluorophenyl}methyl)guanidine; 1- [(3-{ [3-(trifluoromethyl)phenyl]methoxy }phenyl)methyl]guanidine; l-[(2,6-difluoro-3-{ [3- (trifluoromethyl)phenyl]methoxy}phenyl)methyl]guanidine; l-({3-[(2,5-dichlorophenyl) methoxyjphenyl }methyl)guanidine; 1 -[(3- { [4-(trifluoromethyl)phenyl]methoxy } phenyl)methyl] guanidine ; 1 -( { 3 - [(3 ,4-dichlorophenyl)methoxy] phenyl } methyl)guanidine ; 1 - ({3-[(4-chlorophenyl)methoxy]phenyl}methyl)guanidine; l-({3-[(4-bromophenyl)methoxy] phenyl}methyl)guanidine; l-(4-((3,4-dichlorobenzyl)oxy)benzyl)guanidine; l-({3-[(3- chlorophenyl)methoxy]phenyl}methyl)guanidine; 3-(benzyloxy)-N-carbamimidoylbenzamide; l-{ [3-(benzyloxy)phenyl]methyl}guanidine; l-({3-[(2,4-dichlorophenyl)methoxy]phenyl} methyl)guanidine; l-({3-[(4-fluorophenyl)methoxy]phenyl}methyl)guanidine; l-(4- (benzyloxy)benzyl) guanidine; l-[4-(benzyloxy)phenyl]guanidine; l-(4-((3-chlorobenzyl) oxy)benzyl)guanidine; l-{4-[(3-chlorophenyl)methoxy]phenyl}guanidine; l-({3-[(4- chlorophenyl)methoxy]-4-methoxyphenyl}methyl)guanidine; l-(4-((4-chlorobenzyl)oxy) benzyl)guanidine; tert-butyl N-[7-(4-tert-butylphenyl)-l ,2,3,4-tetrahydroisoquinoline-2- carboximidoyl] carbamate; ; 1 - { 4-[(4-chlorophenyl)methoxy]phenyl } guanidine ;; 1 -( { 3 -[(3 - chlorophenyl)methoxy]-4-methoxyphenyl}methyl)guanidine; l-[(3-phenoxyphenyl)methoxy] guanidine ; 4-(4-chlorophenyl)piperazine- 1 -carboximidamide ; 1 -(5 ,6 ,7 , 8 - tetrahydronaphthalen-l-yl)guanidine; 4-(3-methoxyphenyl)piperazine-l-carboximidamide; (E)-Amino(2-(3-((4-chlorobenzyl)oxy)benzylidene)hydrazinyl)methanimine; (E)-Amino(2- (3-((4-(trifluoromethyl)benzyl)oxy)benzylidene) hydrazinyl) methanimine; (E)-Amino(2-(3- ((3-chlorobenzyl)oxy)benzylidene)hydrazinyl)methanimine; (E)-Amino(2-(3-((4- (trifluoromethyl)benzyl)oxy)benzylidene)hydrazinyl) methanimine; (E)-2-(3-((3,4- dichlorobenzyl)oxy)-4-methoxybenzylidene)hydrazine- 1 -carboximidamide ; (E)- Amino(2-(2- chloro-3-((3-chlorobenzyl)oxy)benzylidene)hydrazinyl) methanimine; or a pharmaceutically active salt or N-oxide thereof.

12. A pharmaceutical composition comprising a compound of formula I as defined in any one of claims 1-11, and a pharmaceutically acceptable vehicle.

13. A pharmaceutical composition according to claim 12, further comprising one or more further antibiotics selected from macrolide antibiotics, β-lactam antibiotics, tetracycline antibiotics, and quinolone antibiotics.

14. A pharmaceutical composition according to claim 13 wherein the further antibiotic is selected from azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, telithromycin, CarbomycinA, josamycin, kitasamycin, midecamicine, oleandomycin, spiramycin, tylosin, troleandomycin, aztreonam, imipenem, meropenem, ertapenem, doripenem, panipenem/betamipron, biapenem, PZ-601, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and trovafloxacin, preferably ceftazidime, imipenem/cilastatin, meropenem, aztreonam, oxytetracycline, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, spiramycin and ciprofloxacin.

15. A compound as defined in any one of claims 1 to 11 or a composition as defined in claim 12 or 13 for use as a medicament.

16. A compound as defined in any one of claims 1 to 11 or a composition as defined in claim 12 or 13 for use in the treatment or prophylaxis of a bacterial infection in an animal.

17. A compound or composition for use according to claim 16 wherein the animal is a mammal.

18. A compound or composition for use according to claim 17 wherein the mammal is a human.

19. A compound or composition for use according to any one of claims 16 to 18 wherein the bacterial infection is a Gram-negative bacterial strain infection.

20. A compound or composition for use according to claim 19, wherein the Gram- negative bacterial strain is selected from the group consisting of Escherchia coli, Caulobacter crescentus, Pseudomonas aeruginosa, Agrobacterium tumefaciens, Branhamella catarrhalis, Citrobacter diversus, Enterobacter aerogenes, Enterobacter cloacae, Enterobacter sakazakii, Enterobacter asburiae, Pantoea agglomerans, Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella rhino scleromatis, Proteus mirabilis, Salmonella typhimurium, Salmonella enteriditis, Serratia marcescens, Shigella sonnei, Neisseria gonorrhoeae, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter Iwo fi, Salmonella enteriditis, Fusobacterium nucleatum, Veillonella parvula, Bacteroides forsythus, Actinobacillus actinomycetemcomitans, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Helicobacter pylori, Francisella tularensis, Yersinia pestis, Borrelia burgdorferi, Neisseria meningitidis and Haemophilus influenzae.

21. A compound or composition for use according to any one of claims 16 to 18 wherein the bacterial infection is a Gram-positive bacterial strain infection.

22. A compound or composition for use according to claim 21 wherein the Gram-positive bacterial strain is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus pyogenes, Streptococcus faecalis, Enterococcus faecalis, Enterococcus faecium, Bacillus subtilis, Micrococcus luteus, Mycobacterium tuberculosis, Bacillus anthracis, Bacillus cereus, Clostridium difficile, Propionibacterium acnes, Streptococcus mutans, Actinomyces viscosus, Actinomyces naeslundii, Streptococcus sanguis, Streptococcus pneumoniae and Streptococcus salivarius.

23. A compound or composition for use according to any one of claims 15 to 22 wherein the bacterial infection is a multiple drug- resistant bacterial strain infection.

24. A compound or composition for use according to claim 23 wherein the multiple drug- resistance bacterial strain is selected from the group consisting of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, multiple drug-resistant tuberculosis and multidrug-resistant Clostridium difficile.

25. A method of treatment or prophylaxis of a bacterial infection in an animal comprising administering to an animal in need thereof a therapeutically effective dose of a compound as defined in any one of claims 1 to 11 or a composition as defined in claim 12 or 13.